Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.39 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.39 |
| ▸ | MICA | Q29983 | 2/20 | 0.39 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333118 | 1.00 | CXCR2 (0.43) | CXCR2CTSSCTSKCXCR1P2RX7 | |
| SCHEMBL864493 | 0.87 | DPP4 (0.46) | CXCR2 | |
| SCHEMBL864492 | 0.87 | DPP4 (0.46) | CXCR2 | |
| SCHEMBL5556840 | 0.84 | CXCR2 (0.50) | CXCR2CTSSCTSKCXCR1S1PR3 | |
| SCHEMBL20434046 | 0.83 | CTSS (0.55) | CTSSCTSKKLRK1MICARAET1L | |
| SCHEMBL8665768 | 0.82 | CXCR2 (0.48) | CXCR2CTSSCTSKCXCR1S1PR3 | |
| SCHEMBL13808587 | 0.82 | CXCR2 (0.48) | CXCR2CTSSCTSKCXCR1S1PR3 | |
| SCHEMBL864087 | 0.82 | CYP3A4 (0.44) | — | |
| SCHEMBL864086 | 0.82 | CYP3A4 (0.44) | — | |
| SCHEMBL5445090 | 0.82 | CTSS (0.54) | CTSSCTSKKLRK1MICARAET1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-9815824-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| EP-3013812-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | Nektar Therapeutics (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2010103333-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | CXCR2 1158/4885CTSS 2650/4885CTSK 1903/4885 |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | CXCR2 1158/4885CTSS 2650/4885CTSK 1903/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | CXCR2 1097/4885CTSS 2692/4885CTSK 1939/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | CXCR2 711/4885CTSS 2801/4885CTSK 2741/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | CXCR2 711/4885CTSS 2801/4885CTSK 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.